UR9A Stock Overview
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Clinuvel Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$8.80 |
| 52 Week High | AU$12.40 |
| 52 Week Low | AU$7.70 |
| Beta | 0.74 |
| 1 Month Change | -1.12% |
| 3 Month Change | -4.35% |
| 1 Year Change | -24.14% |
| 3 Year Change | -51.91% |
| 5 Year Change | n/a |
| Change since IPO | -46.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| UR9A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 1.8% | -1.2% |
| 1Y | -24.1% | -19.8% | 1.8% |
Return vs Industry: UR9A underperformed the German Biotechs industry which returned -19.8% over the past year.
Return vs Market: UR9A underperformed the German Market which returned 1.8% over the past year.
Price Volatility
| UR9A volatility | |
|---|---|
| UR9A Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UR9A has not had significant price volatility in the past 3 months.
Volatility Over Time: UR9A's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | Philippe Wolgen | www.clinuvel.com |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Limited Fundamentals Summary
| UR9A fundamental statistics | |
|---|---|
| Market cap | €455.66m |
| Earnings (TTM) | €18.45m |
| Revenue (TTM) | €50.04m |
24.7x
P/E Ratio9.1x
P/S RatioIs UR9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UR9A income statement (TTM) | |
|---|---|
| Revenue | AU$81.76m |
| Cost of Revenue | AU$6.70m |
| Gross Profit | AU$75.06m |
| Other Expenses | AU$44.90m |
| Earnings | AU$30.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.60 |
| Gross Margin | 91.80% |
| Net Profit Margin | 36.88% |
| Debt/Equity Ratio | 0% |
How did UR9A perform over the long term?
See historical performance and comparison